Skip to main content
. Author manuscript; available in PMC: 2013 May 6.
Published in final edited form as: Int J Cancer. 2009 Aug 15;125(4):942–951. doi: 10.1002/ijc.24424

Figure 4. TAT-CTMP4 treatment does not induce apoptosis in human peripheral blood mononuclear cells (PBMC, A.), but does induce levels of apoptosis comparable to other known apoptosis-inducing agents (B.).

Figure 4

Human peripheral blood mononuclear cells were isolated from normal laboratory volunteers. 2.0 – 3.0 × 106 PBMC were incubated for 18 h with PBS (no treatment control), TAT-CTMP4-Inactive (10 µM), TAT-CTMP4 (10 µM), or after being irradiated at 10,000 rads. % active caspase-3 was subsequently measured by flow cytometry. Each experimental group represents an n=5. Results are expressed as the mean, with bars representing standard error of the mean. * = p<0.01. (B) Human model pancreatic adenocarcinoma (Panc-1) were treated with PBS (no treatment), DMSO (vehicle control for wortmannin), wortmannin (1 µM), TAT-CTMP4-Inactive (10 µM), TAT-CTMP4 (10 µM), recombinant human TNF-α (10 ng/ml), gemcitabine (30 nM), and radiation therapy (2000 rads). After 18 hours of treatment, cells were harvested and % active caspase-3 was determined by flow cytometry. Each experimental group represents an n=3. Results are expressed as the mean, with bars representing standard error of the mean.